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Background: Increased serum uric acid has been considered a cardiovascular risk factor but no study has assessed
its relationwith hospitalmortality or length of stay. On the basis of data obtained from a prospective registry, the
prevalence of gout/hyperuricemia and its association with these and other clinical parameters was evaluated in
an Italian cohort of elderly patients acutely admitted to internal medicine or geriatric wards.
Methods:While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia
was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug
was only prescribed owing to the ﬁnding of high serum levels of uric acid. A series of clinical and demographic
variables were evaluated for their association with gout/hyperuricemia.
Results: Of 1380 patients, 139 (10%) had a diagnosis of gout or were prescribed allopurinol. They had more
co-morbidities (7.0 vs 5.6; P b 0.0001) and consumedmore drugs (6.8 vs 5.0; P b 0.0001). The CIRS (co-morbidity
index) was worse in these patients (OR 1.28 95% CI 1.15–1.41). Multivariable regression analysis showed that
only renal and heart failures were independently associated with gout/allopurinol intake. Moreover, this
combined event was associated with an increased risk of adverse events during hospitalization (OR 1.66,
95% CI 1.16–2.36), but not with the risk of re-hospitalization, length of hospital stay or death.
Conclusions:Gout/allopurinol intake has a high prevalence in elderly patients acutely admitted to hospital and are
associated with renal and cardiovascular diseases, an increased rate of adverse events and a high degree of drug
consumption. In contrast, this ﬁnding did not affect the length of hospitalization nor hospital mortality.© 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Gout is a clinical manifestation of hyperuricemia that leads to the
deposition of urate crystals into joints, causing local reactions with
typical signs and symptoms of inﬂammation. The clinical picture of
gout may develop in subjects predisposed to produce high amounts of
uric acid. More commonly, given that uric acid is eliminated through
the kidney, patients with decreased glomerular ﬁltration rate haveessment of Geriatric Therapies
“Mario Negri”, Via La Masa 19,
39001916.
chi).
à Italiana di Medicina Interna).
cine. Published by Elsevier B.V. All rigelevated serum concentrations. Gout prevalence has been increasing
in recent years and is currently one of the most common causes of in-
ﬂammatory arthritis [1]. This disease impacts on healthcare institutions
in terms of health costs and utilization of healthcare services [2]. For in-
stance, Robinson et al. reported an increasing trend in hospital
admission due to gout from 1999 to 2009 [3]. In-hospital gout repre-
sents a signiﬁcant patient and health care burden, with patients
staying 6–7 days longer in hospital [4].
Gout is typically an age-associated disease, because uric acid de-
position progressively increases over the years and gout ﬂares are
correlated with older age [5]. With this background, the aim of this
study was to estimate the prevalence of gout and/or hyperuricemia
prompting the prescription of allopurinol in an Italian population
of patients aged 65 years or older acutely admitted to internal med-
icine or geriatric wards, during four different weeks representing thehts reserved.
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tigate whether or not gout/allopurinol intake in the elderly was asso-
ciated with other demographic or clinical variables, in a particular
length of hospital stay and mortality.
2. Methods
2.1. Study setting and design
This study was conducted in 66 hospital wards (representative of
the Italian internal and geriatric medicine wards), participating
during 2010 in the ‘Registro Politerapie SIMI’ (REPOSI). REPOSI is a
collaborative and independent registry run by the Italian Society of
Internal Medicine (SIMI), the Mario Negri Institute of Pharmacological
Research and the IRCCS Ca' Granda Maggiore Policlinico Hospital
Foundation in Milan. The detailed design of REPOSI is described
elsewhere [6,7]. In brief, patients aged 65 years or more consecutively
admitted to hospital during a period of four weeks, three months
apart from each other, were enrolled in the registry. A standardized
web-based case report form was ﬁlled in by the attending physicians,
including socio-demographic factors, clinical parameters, diagnoses
and medications prescribed both at hospital admission and discharge,
adverse events (AEs) during hospitalization, co-morbidities according
to the Cumulative Illness Rating Scale (CIRS) [8], performance in basic
activities of daily living according to the Barthel Index scale [9], cogni-
tive status according to the Short Blessed Test (SBT) [10] and presence
of depression according to the Geriatric Depression Scale (GDS) [11].
All these data were collected and checked for consistency and accuracy,
with possible contacts of the external contributors, by a central
monitoring institution (the Mario Negri Institute for Pharmacological
Research, Milan).
2.2. Cohort composition
All patients 65 years or older with a diagnosis of gout (International
Classiﬁcation of Disease 9th Edition (ICD-9): 274.xx) made at hospital
admission or during hospital stay or in therapy with allopurinol
(Anatomic Therapeutic Classiﬁcation (ATC): M04AA01) were included
in the study. Because serum levels of uric acid were not reported in
the case report form, it was assumed that the prescription of allopurinol
unrelated to the diagnosis of gout was triggered by the ﬁnding of high
uric acid serum levels. Patients taking allopurinol for chemotherapy or
chronic renal failure were excluded (n = 12). Co-morbidities were
recorded according to the Cumulative Illness Rating Scale (CIRS). The
CIRS co-morbidity index was computed by counting the number of
items for which moderate to severe illness was reported (scores of 3, 4
or 5), while overall illness severity was represented by the mean of the
13 CIRS items [8]. The study was approved by the Ethical Committees of
the IRCCS Cà Granda Maggiore Policlinico Hospital Foundation, Milan,
and of all participating hospitals.
2.3. Statistical analysis
Univariable analyses were applied to compare patients with gout or
treated with allopurinol versus those without these features, and data
were described using means and standard deviations (SD) for numeric
variables or number and percentages for categorical variables, com-
pared applying univariate logistic regression and reported as odds ratios
(OR) and 95% conﬁdence intervals (95% CI). Multivariable logistic
regression analyses assessed the association between gout/allopurinol
intake and presence of other diseases. Selection of variables to be
included in the multivariate model was based on statistical and clinical
signiﬁcance. The analysis was repeated using two different approaches
for co-morbidity: ﬁrst it was adjusted by sex, age, CIRS co-morbidity
index and adverse events, then relevant concomitant diseases replaced
the co-morbidity index. Further analyses were directed to assesswhether or not gout/allopurinol intake were predictors of adverse
events, mortality at discharge, increased length of hospital stay and
readmission. All statistical calculations were performed with the
software JMP Pro 10 (SAS Institute Inc.).
3. Results
Of 1380 enrolled patients, 1368 (99%) were included in the study:
139 (10%) had a diagnosis of gout or were taking allopurinol (exposed
group), whereas the remaining 1229 represented the non-exposed
group (Table 1). Table 1 also shows the socio-demographic and clinical
characteristics of the exposed and non-exposed patients and factors
associated with gout diagnosis or allopurinol intake. Even though
65 years was the limit for admission to the study, the average patient
age was much higher, with no statistically signiﬁcant difference
between the two groups even though the exposed patients tended
to be older.
By univariable analysis, the exposed group showed the following
statistically signiﬁcant differences in comparison with the non-
exposed group. Patients with gout/allopurinol intake were more
often males (61% vs 48%; P = 0.003) and their body mass index
(BMI) was higher than that of the remaining patients (27.7 vs
25.8%; P = 0.0004). Patients with gout/allopurinol intake was also
characterized by a higher number of concomitant diagnoses at
hospital admission (mean: 6.8 vs 5.6; P b 0.0001) and consumed
more drugs other than allopurinol (6.8 vs 5.0; P b 0.0001): more
sulfonamides (73%), proton pump inhibitors (52%), statins (32%),
vitamin K antagonists (27%), nitrates (26%), beta blocking agents
(25%) and angiotensin-II antagonists (23%). At admission the CIRS
co-morbidity index (3.6 vs 2.8; P b 0.001) and the severity index
(1.8 vs 1.6, P b 0.001) were worse in patients with gout/allopurinol
intake. The diagnoses more frequently associated to gout/allopurinol
intake were hypertension (85% vs 76%, P = 0.011), chronic renal
failure (45% vs 14%, P b 0.0001), diabetes (37% vs 26%, P = 0.005),
heart failure (37% vs 14%, P b 0.0001) and coronary artery disease
(30% vs 21%, P = 0.025).
On the other hand, there was no difference between the two groups
for the rates of atrial ﬁbrillation, COPD, cerebrovascular disease and
malignancy. Moreover, there was no signiﬁcant difference pertaining
to smoking and alcohol intake, Barthel Index, SBT andGDS at admission,
nor for duration of hospital stay andmortality. After adjustment for var-
iables statistically signiﬁcant at univariable analysis, the multivariable
regression analyses (Table 2) restricted the number of signiﬁcantly dif-
ferent variables only to chronic renal failure (OR 3.56, 95% CI 2.39–5.31)
and heart failure (OR 2.63, 95% CI 1.75–3.92).
Table 2 also shows that having a diagnosis of gout or taking
allopurinol was also associated to an increased risk to have adverse
events (AEs) during hospitalization (OR 1.66, 95% IC 1.16–2.36),
but not with the risk of re-hospitalization, length of hospital stay or
in-hospital mortality. The most frequent AEs were urinary tract infec-
tions (10.1%), hypokalemia (3.6%), anemia (3.6%), pneumonia (3.6%),
heart failure (3.6%), respiratory tract infections (2.8%), atrial ﬁbrillation
(2.1%), fever (1.4%), renal failure (1.4%) and bacteremia (1.4%).
4. Discussion
This study shows that gout and/or allopurinol intake presumably
due to hyperuricemia is very frequent diagnoses in elderly patients
admitted to internal medicine or geriatric wards, because they were re-
ported in about 10% of people acutely admitted to the hospital because
of different causes and diagnoses. This prevalence is high, especially
considering that the prevalence of gout is 0.46% in the Italian general
population [12], similar to that of other Mediterranean countries [13].
It must be considered that prevalence of gout and hyperuricemia
are rapidly growing and that the population analyzed was at high
risk, being old and hospitalized. Only cardiac and renal failures
Table 1
Sociodemographic and clinical characteristics of patients with or without gout/allopurinol intake (univariable analysis).
Socio-demographic and clinical characteristics
Variables Allopurinol intake or gout
Yes (N = 139) No (N = 1229) Odds ratio (95% CI) P value
Age, mean (SD) 80.0 (7.1) 78.8 (7.3) 1.02 (1.00–1.04) 0.058
Risk factors, N (%)
Smoker 14 (10.0) 109 (8.8) 1.15 (0.63–2.06) 0.65
Heavy alcohol drinker 70 (50.3) 510 (41.6) 1.42 (1.00–2.01) 0.051
Number of patients at admission with 5 or more diagnoses, mean (SD) 91 (65.4) 588 (47.9) 2.06 (1.42–2.97) b .0001
Number of patient at admission taking 5 or more drugs, N (%) 113 (81.2) 675 (54.9) 3.57 (2.33–5.65) b .0001
Severity index at admission, mean (SD) 1.8 (0.3) 1.6 (0.3) 5.13 (3.02–8.71) b .0001
CIRS comorbidity index at admission, mean (SD) 3.6 (1.6) 2.8 (1.7) 1.28 (1.15–1.41) b .0001
Barthel at admission, mean (SD) 77.6 (32.4) 77.4 (30.3) 1.00 (1.00–1.00) 0.101
Short blessed test, mean (SD) 10.9 (8.8) 9.7 (8.0) 1.02 (0.99–1.04) 0.141
Geriatric depression scale, mean (SD) 1.5 (1.2) 1.4 (1.2) 1.13 (0.98–1.30) 0.107
Duration of hospital stay, mean (SD) 10.9 (8.9) 10.7 (8.1) 1.00 (0.98–1.02) 0.787
Adverse clinical events during hospitalization, N (%) 63 (45.3) 410 (33.3) 1.65 (1.16–2.36) 0.006
Hospital mortality, N (%) 8 (5.8) 40 (3.3) 1.81 (0.83–3.95) 0.160
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associations can be attributed to the well established risk to develop
cardiovascular complication in patients with urate overproduction/
decreased elimination [14,15]. Another hypothesis is that many patients
with gout or hyperuricemia share with those with cardiovascular
or renal diseases some frequent risk factors such as overweight,
hypertension, coronary artery disease and diabetes [16,17].
Another ﬁnding of this studywas that patientswith gout/allopurinol
intake experienced during hospitalization a higher number of AEs that
were often severe, including bacterial infections, heart and renal failure
and arrhythmias. Accordingly, particular care and attention should be
devoted when elderly patients with gout or allopurinol therapy are
hospitalized pertaining to the functions of the cardiovascular system
and the kidney. Prevention of these complications might be obtained
by avoiding excessive diuretic medications in patients with increased
serum creatinine according to the deﬁnition of acute kidney injury
(an increase of 50% above the basal value or of 0.3 mg/dl within 48 h)
and, on the other hand, by reducing or stopping ﬂuid infusion in those
with early signs of impending cardiac failure. Another very importantTable 2
Association of gout and/or allopurinol intake with the incidence of adverse events during
hospitalization (univariable and multivariable analysis).
Variables OR (95% CI) P value
1. Univariable analysis
Patients with gout/allopurinol intake 1.66 (1.16–2.36) 0.006
2. Multivariable analysis adjusted for age, sex, AEs and CIRS comorbidity index.
Patients with gout/allopurinol intake 1.52 (1.06–2.19) 0.024




N = 85 1.89 (1.37–2.60)
CIRS comorbidity index 1.07 (1.00–1.15) 0.036
3. Multivariable analysis adjusted for age, sex and associated diseases.
Patients with gout/allopurinol intake 1.48 (1.02–2.16) 0.041




N = 85 1.91 (1.38–2.64)
Hypertension 0.89 (0.69–1.16) 0.380
Chronic renal insufﬁciency 1.27 (0.93–1.73) 0.138
Diabetes mellitus 0.89 (0.68–1.16) 0.390
Heart failure 1.13 (0.83–1.53) 0.431
Ischemic heart disease 0.94 (0.71–1.24) 0.659recommendation is to implement any possible effort to reduce the
burden of infectious agents in the environment.
Our study did not show a relationship between gout/allopurinol
intake and an increased risk of re-hospitalization, length of hospital stay
or in-hospital mortality. In contrast, a previous study [4] showed that
hospitalized patients with acute gout stayed 6 days longer than controls,
perhaps because goutwas a complicating factor for hospitalization owing
to other reasons. Moreover, Robinson et al. showed that patients with
hospital admissions secondarily complicated by gout had a poorer
survival compared with those admitted primarily for gout [3].
In general, the in-hospital management of elderly patients should
take into account the frequent association with co-morbidities.
The BMI of our cohort was indeed signiﬁcantly higher in these
patients, consistently with knowledge that overweight or obesity is a
well established risk factor for abnormal glucose and lipidmetabolisms.
Unfortunately, the data collected in the REPOSI registry did not include
also the serum levels of glucose, cholesterol and tryglicerides. However,
patients with gout/allopurinol intake often took medications such as
statins, which are prescribed in order to decrease serum lipid concen-
trations. Furthermore, at univariate analysis, gout/allopurinol intake
was associated with the diagnosis of diabetes, suggesting once
more that similar pathogenic mechanisms exist for gout,
hyperuricemia, diabetes and dyslipidemia. Indeed, studies in elderly
people with pre-diabetes suggested that high uric acid levels raise a
personal chance to become diabetic [18].
The present study has also shown that patients with gout and/or
allopurinol intake took a greater number of drugs to treat the fre-
quent multiple concomitant diseases. This prescription behavior
raises the issue of the usefulness of basing drug prescription solely
on the simple sum of different diagnoses, because in the elderly the
effects of many drugs may be magniﬁed or reduced due to pharma-
codynamic changes and/or important interactions between the
many prescribed medications. Accordingly, an individually tailored
therapy should take into account the risk of interactions with con-
current medications. In particular, drugs with an excretion pathway
common to that of uric acid should be prescribed with caution, be-
cause in these instances side effects could be early and severe.
The present study has limitations. The main weakness was that the
diagnosis of high serum concentrations of uric acid was not based on
the direct dosage of this moiety in patient serum, but mainly inferred
from the ﬁnding of allopurinol intake. This assumption was based on
the belief that it is unlikely that a drug not free of adverse events such
as allopurinol is prescribed in the presence of normal serum levels of
uric acid, even though we are also cognizant that not all patients with
hyperuricemia beneﬁt from allopurinol intake. By contrast, there are
also some strength that are mainly related to the prospective data
850 C. Franchi et al. / European Journal of Internal Medicine 25 (2014) 847–852collection and the participation of more than 70wards of general hospi-
tals, making the study representative of a wide area in Southern Europe.
5. Learning points
• Gout and/or hyperuricemia is frequent in elderly patients admitted to
internal medicine wards.
• Only cardiac and renal failures were signiﬁcantly associated with
gout/allopurinol intake.
• Gout or taking allopurinol was associated to an increased risk of
hospital adverse events.
• Gout or allopurinol intake should prompt to look for cardiovascular or
renal diseases, drug interactions and clinical risks.
Disclosure statement
All authors have no conﬂicts of interests to disclose
Appendix A. Investigators and co-authors of the REPOSI (REgistro
POliterapie SIMI, Società Italiana di Medicina Interna) Study Group
are as follows:
Steering Committee: Pier Mannuccio Mannucci (Chair, Fondazione
IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano), Alessandro
Nobili (co-chair, IRCCS—Istituto di Ricerche Farmacologiche “Mario
Negri”, Milano), Mauro Tettamanti, Luca Pasina, Carlotta Franchi
(IRCCS—Istituto di Ricerche Farmacologiche “Mario Negri”, Milano),
Francesco Salerno (IRCCS Policlinico San Donato Milanese, Milano),
Salvatore Corrao (ARNAS Civico, Di Cristina, Benfratelli, DiBiMIS,
Università di Palermo, Palermo), Alessandra Marengoni (Spedali Civili di
Brescia, Brescia), Maura Marcucci (Dipartimento di Medicina Interna,
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano).
Clincal data monitoring and revision: Eleonora Sparacio, Stefania
Alborghetti, Rosa Di Costanzo (IRCCS—Istituto di Ricerche Farmacologiche
“Mario Negri”, Milano).
Database Management and Statistics: Mauro Tettamanti, Codjo
Djignefa Djade (IRCCS—Istituto di Ricerche Farmacologiche “Mario
Negri”, Milano).
Investigators:
Domenico Prisco, Elena Silvestri, Caterina Cenci, Tommaso Barnini
(Azienda Ospedaliero Universitaria Careggi Firenze, SOD Patologia
Medica); Giuseppe Delitala, Stefano Carta, Sebastiana Atzori (Azienda
Mista Ospedaliera Universitaria, Sassari, Clinica Medica); Gianfranco
Guarnieri, Michela Zanetti, Annalisa Spalluti (Azienda Ospedaliera
Universitaria Ospedali Riuniti di Trieste, Trieste, Clinica Medica Generale e
Terapia Medica); Maria Grazia Serra, Maria Antonietta Bleve (Azienda
Ospedaliera “Cardinale Panico” di Tricase, Lecce, Unità Operativa
Complessa Medicina);Massimo Vanoli, Giulia Grignani, Gianluca Casella
(Azienda Ospedaliera della Provincia di Lecco, Ospedale di Merate, Lecco,
Medicina Interna); Laura Gasbarrone (Azienda Ospedaliera Ospedale San
Camillo Forlanini, Roma, Medicina Interna 1); Giorgio Maniscalco,
Massimo Gunelli, Daniela Tirotta (Azienda Ospedaliera Ospedale San
Salvatore, Pesaro, Soc Medicina Interna); Antonio Brucato, Silvia Ghidoni,
Paola Di Corato (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo,
Medicina 1); Mauro Bernardi, Silvia Li Bassi, Luca Santi (Azienda
Ospedaliera Policlinico Sant'Orsola-Malpighi, Bologna, Semeiotica Medica
Bernardi); Giancarlo Agnelli, Alfonso Iorio, Maura Marcucci, Emanuela
Marchesini (Azienda Ospedaliera Santa Maria della Misericordia,
Perugia, Medicina Interna e Cardiovascolare); Elmo Mannarino, Graziana
Lupattelli, Pamela Rondelli, Francesco Paciullo (Azienda Ospedaliera
Santa Maria della Misericordia, Perugia, Medicina Interna, Angiologia,
Malattie da Arteriosclerosi); Fabrizio Fabris, Michela Carlon, FrancescaTuratto (Azienda Ospedaliera Università di Padova, Padova, Clinica
Medica I); Maria Cristina Baroni, Marianna Zardo (Azienda Ospedaliera
Università di Parma, Parma, Clinica e Terapia Medica); Roberto
Manfredini, Christian Molino, Marco Pala, Fabio Fabbian (Azienda
Ospedaliera — Universitaria Sant'Anna, Ferrara, Unità Operativa Clinica
Medica); Ranuccio Nuti, Roberto Valenti, Martina Ruvio, Silvia Cappelli
(Azienda Ospedaliera Università Senese, Siena, Medicina Interna I);
Giuseppe Paolisso, Maria Rosaria Rizzo, Maria Teresa Laieta (Azienda
Ospedaliera Universitaria della Seconda Università degli Studi di Napoli,
Napoli, VI Divisione di Medicina Interna e Malattie Nutrizionali
dell'Invecchiamento); Teresa Salvatore, Ferdinando Carlo Sasso (Azienda
Ospedaliera Universitaria della Seconda Università degli Studi di Napoli,
Napoli, Medicina Interna e Malattie Epato-Bilio Metaboliche Avanzate);
Riccardo Utili, Emanuele Durante Mangoni, Daniela Pinto (Azienda
Ospedaliera Universitaria della Seconda Università degli Studi di Napoli,
Napoli, Medicina Infettivologica e dei trapianti); Oliviero Olivieri, Anna
Maria Stanzial (Azienda Ospedaliera Universitaria Integrata di Verona,
Verona, Unità Operativa di Medicina Interna B); Renato Fellin,
Stefano Volpato, Sioulis Fotini (Azienda Ospedaliera Universitaria
Ospedale Sant'Anna, Ferrara, Unità Operativa di Medicina Interna
Gerontologia e Geriatria); Mario Barbagallo, Ligia Dominguez, Lidia
Plances, Daniela D'Angelo (Azienda Ospedaliera Universitaria Policlinico
Giaccone Policlinico di Palermo, Palermo, Unità Operativa di Geriatria e
Lungodegenza); Giovanbattista Rini, Pasquale Mansueto, Ilenia Pepe
(Azienda Ospedaliera Universitaria Policlinico P. Giaccone di Palermo,
Palermo, Medicina Interna e Malattie Metaboliche); Giuseppe Licata,
Luigi Calvo, Maria Valenti (Azienda Ospedaliera Universitaria Policlinico
P. Giaccone di Palermo, Palermo, Medicina Interna e Cardioangiologia);
Claudio Borghi, Enrico Strocchi, Elisa Rebecca Rinaldi (Azienda
Ospedaliera Universitaria Policlinico S. Orsola-Malpighi, Bologna,
Unità Operativa di Medicina Interna Borghi); Marco Zoli, Elisa Fabbri,
Donatella Magalotti (Azienda Ospedaliera Universitaria Policlinico
S. Orsola-Malpighi, Bologna, Unità Operativa di Medicina Interna
Zoli); Alberto Auteri, Anna Laura Pasqui, Luca Puccetti (Azienda
Ospedaliera Universitaria Senese, Siena, Medicina 3); Franco Laghi
Pasini, Pier Leopoldo Capecchi, Maurizio Bicchi (Azienda Ospedaliera
Universitaria Senese, Siena, Unità Operativa Complessa Medicina 2);
Carlo Sabbà, Francesco Saverio Vella, Alessandro Marseglia, Chiara
Valentina Luglio (Azienda Ospedaliero—Universitaria Consorziale
Policlinico di Bari, Bari, Medicina Interna Universitaria C. Frugoni);
Giuseppe Palasciano, Maria Ester Modeo, Annamaria Aquilino, Pallante
Raffaele (Azienda Ospedaliero—Universitaria Consorziale Policlinico di
Bari, Bari, Medicina Interna Ospedale “Pende-Ferrannini”); Stefania
Pugliese, Caterina Capobianco (Azienda Ospedaliero—Universitaria
Consorziale Policlinico di Bari, Bari, Clinica Medica I Augusto Murri);
Alfredo Postiglione, Maria Rosaria Barbella, Francesco De Stefano
(Azienda Ospedaliera Universitaria Policlinico Federico II di Napoli,
Medicina Geriatrica Dipartimento di Clinica Medica); Luigi Fenoglio,
Chiara Brignone, Christian Bracco, Alessia Giraudo (Azienda Sanitaria
Ospedaliera Santa Croce e Carle di Cuneo, Cuneo, S. C. Medicina Interna);
Giuseppe Musca, Olga Cuccurullo (Azienda Sanitaria Provinciale di
Cosenza Presidio Ospedaliero di Cetraro, Cosenza, Unità Operativa
Complessa Medicina Interna); Luigi Cricco, Alessandra Fiorentini (COB
Stabilimento Monteﬁascone, Viterbo, Unità Operativa Complessa di
Geriatria e Medicina); Maria Domenica Cappellini, Giovanna Fabio,
Sonia Seghezzi, Margherita Migone De Amicis (Fondazione IRCCS Cà
Granda Ospedale Maggiore Policlinico, Milano, Unità Operativa Medicina
Interna IA); Silvia Fargion, Paola Bonara, Mara Bulgheroni, Rosa
Lombardi (Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,
Milano, Medicina Interna 1B); Fabio Magrini, Ferdinando Massari,
Tatiana Tonella (Fondazione IRCCS Cà Granda Ospedale Maggiore
Policlinico, Milano, Unità Operativa Medicina Cardiovascolare); Flora
Peyvandi, Alberto Tedeschi, Raffaella Rossio (Fondazione IRCCS Cà
Granda Ospedale Maggiore Policlinico, Milano, Medicina Interna 2);
Guido Moreo, Barbara Ferrari, Luisa Roncari (Fondazione IRCCS Cà
Granda OspedaleMaggiore Policlinico, Milano, Medicina Interna 3); Valter
851C. Franchi et al. / European Journal of Internal Medicine 25 (2014) 847–852Monzani, Valeria Savojardo, Christian Folli, Maria Magnini (Fondazione
IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Medicina
d'Urgenza); Daniela Mari, Paolo Dionigi Rossi, Sarah Damanti, Silvia
Prolo (Fondazione IRCCS Cà GrandaOspedaleMaggiore Policlinico,Milano,
Geriatria); Maria Sole Lilleri (Fondazione IRCCS Cà Granda Ospedale
Maggiore Policlinico, Milano, Medicina Generale ad Indirizzo Geriatrico);
Luigi Cricco, Alessandra Fiorentini (COB Viterbo, Stabilimento
Monteﬁascone, Viterbo, UOC Geriatria e Medicina); Giuliana Micale
(IRCCS Istituto Auxologico Italiano, Milano, Medicina Generale ad indirizzo
Geriatrico); Mauro Podda, Carlo Selmi, Francesca Meda (IRCCS Istituto
Clinico Humanitas, Milano, Clinica Medica); Francesco Salerno, Silvia
Accordino, Alessio Conca, Valentina Monti (IRCCS Policlinico San Donato
e Università di Milano, San Donato Milanese, Medicina Interna); Gino
Roberto Corazza, Emanuela Miceli, Marco Vincenzo Lenti, Donatella
Padula (IRCCS Policlinico San Matteo di Pavia, Pavia, Clinica Medica I,
Reparto 11); Carlo L. Balduini, Giampiera Bertolino, Stella Provini,
Federica Quaglia (IRCCS Policlinico San Matteo di Pavia, Pavia, Clinica
Medica III); Giovanni Murialdo, Marta Bovio (IRCS Azienda Ospedaliera
Universitaria San Martino-IST di Genova, Genova, Clinica di Medicina
Interna 2); Franco Dallegri, Luciano Ottonello, Alessandra Quercioli,
Alessandra Barreca (Università di Genova, Genova, Medicina Interna 1);
Maria Beatrice Secchi, Davide Ghelﬁ (Ospedale Bassini di Cinisello
Balsamo, Milano, Divisione Medicina);Wu Sheng Chin, Laura Carassale,
Silvia Caporotundo (Ospedale Bassini, Cinisello Balsamo, Milano, Unità
Operativa di Geriatria); Luigi Anastasio, Lucia Soﬁa, Maria Carbone
(Ospedale Civile Jazzolino di Vibo Valentia, Vibo Valentia, Medicina
interna); Giancarlo Traisci, Lucrezia De Feudis, Silvia Di Carlo (Ospedale
Civile Santo Spirito di Pescara, Pescara, Medicina Interna 2); Giovanni
Davì, Maria Teresa Guagnano, Simona Sestili (Ospedale Clinicizzato SS.
Annunziata, Chieti, Clinica Medica); Elisabetta Bergami, Emanuela
Rizzioli (Ospedale del Delta, Lagosanto, Ferrara, Medicina Interna); Carlo
Cagnoni, Luca Bertone, Antonio Manucra (Ospedale di Bobbio, Piacenza,
Unità Operativa Medicina e Primo Soccorso); Alberto Buratti, Tiziana
Tognin, Nicola Lucio Liberato (Azienda Ospedaliera della Provincia di
Pavia, Ospedale di Casorate Primo, Pavia, Medicina Interna); Giordano
Bernasconi, Barbara Nardo (Ospedale di Circolo di Busto Arsizio, Varese,
Medicina I); Giovanni Battista Bianchi, Sabrina Giaquinto Ospedale
“SS Gerosa e Capitanio” di Lovere, Bergamo, Unità Operativa Complessa
diMedicinaGenerale, AziendaOspedaliera “Bolognini” di Seriate, Bergamo;
Giampiero Benetti, Michela Quagliolo, Giuseppe Riccardo Centenaro
(Ospedale di Melegnano, Vizzolo Predabissi, Melegnano, Medicina 1);
Francesco Purrello, Antonino Di Pino, Salvatore Piro (Ospedale Garibaldi
Nesima, Catania, Unità Operativa Complessa di Medicina Interna);
Gerardo Mancuso, Daniela Calipari, Mosè Bartone, Francesco Gullo
(Ospedale Giovanni Paolo II Lamezia Terme, Catanzaro, Unità Operativa
Complessa Medicina Interna); Michele Cortellaro, Marina Magenta,
Francesca Perego; Maria Rachele Meroni (Ospedale Luigi Sacco, Milano,
Medicina 3°);Marco Cicardi, Antonio Gidaro Marina Magenta (Ospedale
Luigi Sacco, Milano, Medicina II); Andrea Sacco, Antonio Bonelli, Gaetano
Dentamaro (Ospedale Madonna delle Grazie, Matera, Medicina); Renzo
Rozzini, Lina Falanga, Alessandro Giordano (Ospedale Poliambulanza,
Brescia, Medicina Interna e Geriatria); Paolo Cavallo Perin, Bartolomeo
Lorenzati, Gabriella Gruden, Graziella Bruno (Dipartimento di Scienze
Mediche, Università di Torino, Città della Scienza e della Salute, Torino,
Medicina 3); Giuseppe Montrucchio, Elisabetta Greco, Pietro Tizzani
(Dipartimento di Scienze Mediche, Università di Torino, Città della Scienza
e della Salute, Torino, Medicina Interna 5); Giacomo Fera, Maria Loreta Di
Luca, Donatella Renna (Ospedale San Giacomo di Monopoli, Bari, Unità
Operativa Medicina Interna); Antonio Perciccante, Alessia Coralli
(Ospedale San Giovanni-Decollato-Andisilla, Civita Castellana Medicina);
Rodolfo Tassara, Deborah Melis, Lara Rebella (Ospedale San Paolo,
Savona, Medicina I); Giorgio Menardo, Stefania Bottone, Elsa Sferrazzo
(Ospedale San Paolo, Savona,Medicina Interna eGastroenterologia);Claudio
Ferri, Rinaldo Striuli, Rosa Scipioni (Ospedale San Salvatore, L'Aquila,
Medicina Interna Universitaria); Raffaella Salmi, Piergiorgio Gaudenzi,
Susanna Gamberini, Franco Ricci (Azienda Ospedaliera—UniversitariaS. Anna, Ferrara, Unità Operativa di Medicina Ospedaliera II); Cosimo
Morabito, Roberto Fava (Ospedale Scillesi d'America, Scilla Medicina);
Andrea Semplicini, Lucia Gottardo (Ospedale SS. Giovanni e Paolo, Venezia,
Medicina Interna 1); Giuseppe Delitala, Stefano Carta, Sebastiana Atzori
(Ospedale Universitario Policlinico di Sassari, Sassari, Clinica Medica);
Gianluigi Vendemiale, Gaetano Serviddio, Roberta Forlano (Ospedali
Riuniti di Foggia, Foggia, Medicina Interna Universitaria); Luigi Bolondi,
Leonardo Rasciti, Ilaria Serio (Policlinico Sant'Orsola-Malpighi, Bologna,
Unità Operativa Complessa Medicina Interna); Cesare Masala, Antonio
Mammarella, Valeria Raparelli (Policlinico Umberto I, Roma, Medicina
Interna D); Filippo Rossi Fanelli, Massimo Delﬁno, Antonio Amoroso
(Policlinico Umberto I, Roma, Medicina Interna H); Francesco Violi, Stefania
Basili, Ludovica Perri (Policlinico Umberto I, Roma, Prima Clinica Medica);
Pietro Serra, Vincenzo Fontana, Marco Falcone (Policlinico Umberto I,
Roma, Terza Clinica Medica); Raffaele Landolﬁ, Antonio Grieco, Antonella
Gallo (Policlinico Universitario A. Gemelli, Roma, Clinica Medica); Giuseppe
Zuccalà, Francesco Franceschi, Guido De Marco, Cordischi Chiara,
Sabbatini Marta (Policlinico Universitario A. Gemelli, Roma, Roma, Unità
Operativa Complessa Medicina d'Urgenza e Pronto Soccorso); Martino
Bellusci, Donatella Setti, Filippo Pedrazzoli (Presidio Ospedaliero Alto
Garda e Ledro, Ospedale di Arco, Trento, Unità Operativa di Medicina Interna
Urgenza/Emergenza);Giuseppe Romanelli, Caterina Pirali, Claudia Amolini
(Spedali Civili di Brescia, Brescia, Geriatria); Enrico Agabiti Rosei, Damiano
Rizzoni, LuanaCastoldi (Spedali Civili di Brescia, Brescia, SecondaMedicina);
Antonio Picardi, Umberto Vespasiani Gentilucci, Chiara Mazzarelli, Paolo
Gallo (Università Campus Bio-Medico, Roma, Medicina Clinica-Epatologia);
Luigina Guasti, Luana Castiglioni, Andrea Maresca, Alessandro Squizzato,
Sara Contini, Marta Molaro (Università degli Studi dell'Insubria, Ospedale
di Circolo e FondazioneMacchi, Varese, Medicina Interna I);Giorgio Annoni,
Maurizio Corsi, Sara Zazzetta (Università degli studi di Milano-Bicocca
Ospedale S. Gerardo, Monza, Unità Operativa di Geriatria);Marco Bertolotti,
Chiara Mussi, Roberto Scotto, Maria Alice Ferri, Francesca Veltri
(Università di Modena e Reggio Emilia, AUSL di Modena, Modena, Nuovo
Ospedale Civile, Unità Operativa di Geriatria); FrancoArturi, Elena Succurro,
Giorgio Sesti, Umberto Gualtieri (Università degli Studi Magna Grecia,
PoliclinicoMater Domini, Catanzaro, Unità Operativa Complessa di Medicina
Interna); Francesco Perticone, Angela Sciacqua, Michele Quero, Chiara
Bagnato (Università Magna Grecia Policlinico Mater Domini, Catanzaro,
Unità Operativa Malattie Cardiovascolari Geriatriche); Paola Loria,
Maria Angela Becchi, Gianfranco Martucci, Alessandra Fantuzzi, Mauro
Maurantonio (Università di Modena e Reggio Emilia, Medicina Metabolica-
NOCSAE, Baggiovara, Modena); Roberto Corinaldesi, Roberto De Giorgio,
Mauro Serra, Valentina Grasso, Eugenio Ruggeri, Lorenzo Mauro Carozza,
Fabio Pignatti (Dipartimento di Scienze Mediche e Chirurgiche, Unità
Operativa di Medicina Interna, Università degli Studi di Bologna/Azienda
Ospedaliero—Universitaria S. Orsola-Malpighi, Bologna).References
[1] Richette P, Bardin T. Gout. Lancet 2010;375:318–28.
[2] Trieste L, Palla I, Fusco F, Tani C, Baldini C,MoscaM, et al. The economic impact of gout: a
systematic literature review. Clin Exp Rheumatol 2012;30(4 Suppl. 73):S145–8.
[3] Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated
with gout and their comorbidities in New Zealand and England 1999–2009.
Rheumatology (Oxford) 2013;52:118–26.
[4] Lee G, Roberts L. Healthcare burden of in-hospital gout. Intern Med J 2012 Nov;
42(11):1261–3.
[5] Kim KY, Schumacher HR, Hunsche E, Wertheimer AI, Kong SH. A literature
review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:
1593–617.
[6] Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, et al. Polypharmacy,
length of hospital stay, and in-hospital mortality among elderly patients in internal
medicine wards. The REPOSI study. Eur J Clin Pharmacol 2011;67:507–19.
[7] Franchi C, Nobili A, Mari D, Tettamanti M, Djade CD, Pasina L, et al, on behalf of
REPOSI Investigators. Risk factors for hospital readmission of elderly patients. Eur J
Intern Med 2013 Jan;24(1):45–51. http://dx.doi.org/10.1016/j.ejim.2012.10.005
[Epub 2012 Nov 8].
[8] Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of a measure of physical
burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc 1995;43:
130–7.
852 C. Franchi et al. / European Journal of Internal Medicine 25 (2014) 847–852[9] Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke
rehabilitation. J Clin Epidemiol 1989;42:703–9.
[10] Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short
orientation–memory–concentration test of cognitive impairment. Am J Psychiatry
1983;140:734–9.
[11] Hickie C, Snowdon J. Depression scales for the elderly: GDS, Gilleard, Zung. Clin
Gerontol 1987;6:51–3.
[12] Salafﬁ F, De Angelis R, Grassi W, MArche Pain Prevalence, INvestigation Group
(MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population
sample: results of a regional community-based study. I. The MAPPING study. Clin
Exp Rheumatol 2005;23:819–28.
[13] Smith EU, Díaz-Torné C, Perez-Ruiz F, March LM. Epidemiology of gout: an update.
Best Pract Res Clin Rheumatol 2010;24:811–27.[14] Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term
cardiovascular mortality among middle-aged men with gout. Arch Intern Med
2008;168:1104–10.
[15] Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acutemyocardial
infarction. Arthritis Rheum 2006;54:2688–96.
[16] Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG. Prevalence of
comorbid conditions and prescription medication use among patients with gout
and hyperuricemia in a managed care setting. J Clin Rheumatol 2004;10:308–14.
[17] Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence,
comorbidities and management in general practice 2000–2005. Ann Rheum Dis
2008;67:960–6.
[18] Bhole V1, Choi JW, Kim SW, de VeraM, Choi H. Serum uric acid levels and the risk of
type 2 diabetes: a prospective study. Am J Med Oct 2010;123(10):957–61.
